| Form | Liquid |
|---|---|
| Host Species | Human |
| Clonality | Monoclonal |
| Isotype | IgG4-kappa |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Concentration | 1mg/ml |
| Endotoxin Level | Please contact the lab for this information. |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Species Reactivity | Human |
| Target | Herpes virus entry mediator ligand, LIGHT, CD258, HVEM-L, HVEML, TNFSF14, Tumor necrosis factor ligand superfamily member 14, Herpesvirus entry mediator ligand |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Expression System | Mammalian Cells |
| Accession Number | O43557 |
| Background | Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies. • LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells., PMID:33606781 • LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells., PMID:27835685 • Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth., PMID:9765287 • A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis., PMID:10318773 |
| Alternative Names | AEVI-002, CERC-002, F-19, MDGN-002, SAR-2520672427667-03-4 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |